ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 976

Identification of Novel Genes Associated with Dysregulation of B Cells in Patients with Primary Sjögren’s Syndrome

Jun Inamo1, Katsuya Suzuki 2, Masaru Takeshita 2, Yoshiaki Kassai 3, Maiko Takigchi 4, Rina Kurisu 4, Yuumi Okuzono 4, Shinya Tasaki 5 and Tsutomu Takeuchi 6, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 3Immunology Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Shinjuku-ku, Tokyo, Japan, 4Immunology Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Shinjuku-ku, Japan, 5Integrated Technology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Shinjuku-ku, Japan, 6Keio University School of Medicine, Tokyo, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: B cells and basic research, Bioinformatics, Gene Expression, Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Dysregulation of B cells play a critical role in the pathogenesis of primary Sjögren’s syndrome (pSS). Long non-coding RNAs (lncRNAs), which have become the focus of studies on autoimmune diseases, may contribute to the pathogenesis of pSS through multiple signal transduction pathways. However, no study focuses on the effects of dysregulation of the transcriptomes, including lncRNAs, of B cells on the pathogenesis of pSS. The aim of this study was to identify the molecular mechanism of dysregulation of B cell subpopulations of pSS at the transcriptome level.

Methods: We enrolled patients with pSS (n=6) and healthy controls (HC) (n=6). Peripheral B cells acquired from these subjects were separated by cell sorting into four subsets: CD38–IgD+ (Bm1), CD38+IgD+ (naïve B cells), CD38highIgD+ (pre-germinal centre B cells), and CD38±IgD– (memory B cells). Total RNA was extracted, and gene expression was measured using microarrays. We conducted a bioinformatics analysis to identify differentially expressed genes (DEGs) and weighted gene co-expression network analysis (WGCNA) to identify pSS-associated signalling pathways. We validated gene expression levels in CD19+ B cells of patients with pSS (n=7) and HC (n=7) in other cohorts by quantitative PCR (qPCR).

Results: Using principal component and clustering analyses, we found that transcript expression patterns depended on cell type rather than clinical condition (pSS or HC). DEGs analysis identified LINC00487 as significantly upregulated in all B cell subsets as well as HLA and interferon signature genes. Moreover, the normalized intensity value of LINC00487 significantly correlated with the disease activity score in all pSS B cell subsets (Figure 1). An in vitro study using human B cell lines revealed that the expression of LINC00487 was strongly induced by IFNα. In validation cohort using qPCR, expression of LINC00487 in CD19+ B cells of patients with pSS tended to upregulate compared with HC, although it was not significant (relative expression levels of LINC00487/GDH; 0.00227 vs 0.00025, p = 0.12). Further, expression of LINC00487 was significantly correlated with interferon stimulated gene, interferon induced protein 44 like (IFI44L). WGCNA revealed six clusters associated with the B cell subpopulation of pSS. Further, genes that encode components of the B cell receptor (BCR) signaling pathway were identified as intramodule hub genes such as IKZF3 and HRK. SOX4, which may be targeted by several microRNAs identified in upstream analysis, was identified as an inter-module hub gene (Figure 2).

Conclusion: Our transcriptome analysis revealed key genes involved in the molecular dysregulation of B cell subpopulations associated with pSS. This knowledge contributes to our understandings of the pathogenesis of pSS.

Figure 1. Scatter plot of disease activity score and relative expression level of LINC00487 in CD38-IgD+ -Bm1-, CD38+IgD+ -naïve-, CD38highIgD+ -pre GC-B- and CD38±IgD- -memory- subset of patients with primary Sjögren’s syndrome.

Figure 2. Associativity of intra- and inter-modular hub genes in B cells of pSS. Node-color corresponds with module-color. Green-coded edge means positive correlation and red-coded edge means negative correlation, respectively. The width of edge reflects absolute weight of correlation.


Disclosure: J. Inamo, None; K. Suzuki, AbbVie, 2, Bristol-Myers Squibb, 2, Chugai, 2, Daiichi-Sankyo, 2, Eisai, 2, Fuji Film, 2, Kissei, 2, Mitsubishi Tanabe, 2, Ono, 2, Pfizer, 2, Takeda Pharmaceutical, 2; M. Takeshita, Novartis, 2; Y. Kassai, Takeda Pharmaceutical Co,. Ltd., 3; M. Takigchi, Takeda Pharmaceutical Co,. Ltd., 3; R. Kurisu, Takeda Pharmaceutical Co,. Ltd., 3; Y. Okuzono, Takeda Pharmaceutical Co,. Ltd., 3; S. Tasaki, Takeda Pharmaceutical Co,. Ltd., 3; T. Takeuchi, AbbVie, 2, 5, 8, AbbVie GK, 2, 9, Asahi Kasei, 2, Asahikasei, 2, Asahikasei Pharma Corp., 2, Astellas, 2, 8, 9, Astellas Pharma Inc, 2, Astellas Pharma, Inc., 2, 5, 8, 9, Astra Zeneca, 2, AstraZeneca, 8, AYUMI, 2, 9, AYUMI Pharmaceutical Corporation, 2, BMS, 2, 8, Boehringer-ingelheim, 9, Bristol–Myers K.K., 9, Bristol-Myers, 2, Bristol-Myers Squibb, 8, Chugai, 2, 8, 9, Chugai Pharmaceutical Co, Ltd., 2, Daiichi Sankyo, 2, 8, 9, Daiichi Sankyo Co., Ltd., 2, Eisai, 2, 5, 8, 9, Eisai Co., Ltd., 2, Eli Lilly, 2, 8, Eli Lilly Japan, 9, Gilead Sciences, Inc., 9, GlaxoSmithKline K.K, 9, GSK, 8, Janssen, 2, 8, Janssen Pharmaceutical K.K, 9, Mitsubishi Tanabe, 2, 9, Mitsubishi Tanabe Pharma Co., 2, Mitsubishi-Tanabe Pharma Corp, 2, 8, 9, Nippon Kayaku, 2, Nipponkayaku, 2, 9, Nipponkayaku Co.Ltd., 2, Novartis, 2, 8, Novartis Pharma K.K, 2, 9, Novartis Pharma K.K., 2, Pfizer, 2, 8, Pfizer Japan, 2, 9, Pfizer Japan Inc., 2, Sanofi, 8, Sanofi K.K, 9, Shionogi & Co., 2, Shionogi & Co., LTD., 2, Taiho, 2, 8, 9, Taisho, 9, Taisho Toyama, 2, 8, Takahashi Industrial and Economic Research Foundation, 2, Takeda, 2, 8, Takeda Pharmaceutical Co., Ltd., 2, Teijin, 2, 8, UCB, 8, 9, UCB Japan, 9.

To cite this abstract in AMA style:

Inamo J, Suzuki K, Takeshita M, Kassai Y, Takigchi M, Kurisu R, Okuzono Y, Tasaki S, Takeuchi T. Identification of Novel Genes Associated with Dysregulation of B Cells in Patients with Primary Sjögren’s Syndrome [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/identification-of-novel-genes-associated-with-dysregulation-of-b-cells-in-patients-with-primary-sjogrens-syndrome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-novel-genes-associated-with-dysregulation-of-b-cells-in-patients-with-primary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology